<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30337273</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>1043</StartPage><EndPage>1052</EndPage><MedlinePgn>1043-1052</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(18)30320-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(18)30320-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by CAG repeat expansion in the androgen receptor gene. Patients with this disease have low concentrations of insulin-like growth factor-1 (IGF-1), and studies of overexpression and administration of IGF-1 showed benefit in a transgenic model; thus the IGF-1 pathway presents as a potential treatment target. We assessed safety, tolerability, and preliminary efficacy of BVS857, an IGF-1 mimetic, in patients with spinal and bulbar muscular atrophy.</AbstractText><AbstractText Label="METHODS">In this randomised, double-blind, placebo-controlled trial, we recruited patients from neuromuscular centres in Denmark (Copenhagen), Germany (Ulm), Italy (Padova), and three sites within the USA (Bethesda, MD; Irvine, CA; and Columbus, OH). Eligible patients were 18 years or older with a confirmed genetic diagnosis of spinal and bulbar muscular atrophy, were ambulatory, had symptomatic weakness, and had serum IGF-1 concentrations of 170 ng/mL or lower. Patients were randomly assigned (2:1) to study drug or placebo by a number scheme. Patients, investigators, and study personnel were masked to treatment assignment. After a safety and tolerability assessment with eight patients, BVS857 was administered once a week (0&#xb7;06 mg/kg intravenously) for 12 weeks. Primary outcome measures were safety, tolerability, and the effects of BVS857 on thigh muscle volume (TMV) measured by MRI. The ratio of TMV at day 85 to baseline was analysed with ANCOVA per protocol. Secondary outcomes of muscle strength and function were measured with the Adult Myopathy Assessment Tool, lean body mass through dual energy x-ray absorptiometry, and BVS857 pharmacokinetics. This trial was registered with ClinicalTrials.gov, NCT02024932.</AbstractText><AbstractText Label="FINDINGS">31 patients were assessed for eligibility, 27 of whom were randomly assigned to either BVS857 treatment (n=18) or placebo (n=9), and 24 were included in the preliminary efficacy analysis (BVS857 group, n=15; placebo group, n=9). BVS857 was generally safe with no serious adverse events. No significant differences were found in adverse events between the BVS857 and placebo groups. Immunogenicity was detected in 13 (72%) of 18 patients in the BVS857 group, including crossreacting antibodies with neutralising capacity to endogenous IGF-1 in five patients. TMV decreased from baseline to day 85 in the placebo group (-3&#xb7;4% [-110 cm<sup>3</sup>]) but not in the BVS857 group (0% [2 cm<sup>3</sup>]). A significant difference in change in TMV was observed in the BVS857 group versus the placebo group (geometric-mean ratio 1&#xb7;04 [90% CI 1&#xb7;01-1&#xb7;07]; p=0&#xb7;02). There were no differences between groups in measures of muscle strength and function.</AbstractText><AbstractText Label="INTERPRETATION">TMV remained stable in patients with spinal and bulbar muscular atrophy after being given BVS857 for 12 weeks. The intervention was associated with high incidence of immunogenicity and did not improve muscle strength or function. Additional studies might be needed to assess the efficacy of activating the IGF-1 pathway in this disease.</AbstractText><AbstractText Label="FUNDING">Novartis Pharmaceuticals and the US National Institutes of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grunseich</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: christopher.grunseich@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Ram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swan</LastName><ForeName>Therese</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Mouelhi</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petricoul</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vostiar</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roubenoff</LastName><ForeName>Ronenn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meriggioli</LastName><ForeName>Matthew N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>AveXis Inc, Bannockburn, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokkinis</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budron</LastName><ForeName>Maher S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vissing</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soraru</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozaffar</LastName><ForeName>Tahseen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of California Irvine, ALS and Neuromuscular Center, Orange, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kissel</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wexner Medical Center, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>BVS857 study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02024932</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 NS999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2018 Dec;17(12):1026-1027</RefSource><PMID Version="1">30337274</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests. Drs. Glass and Fischbeck were named as co-inventors on a provisional patent application by Novartis pertaining to the use of IGF-1 related compounds as therapeutic agents in patients with SBMA. Drs. Glass and Fornaro are co-inventors on a patent of BVS857. Ram Miller, Therese Swan, David J Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, and Matthew N Meriggioli are employees of Novartis Institutes for Biomedical Research. All other authors declare that they have no conflicts of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Grunseich</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Ram</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swan</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouelhi</LastName><ForeName>Mohamed El</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petricoul</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vostiar</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roubenoff</LastName><ForeName>Ronenn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meriggioli</LastName><ForeName>Matthew N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahlqvist</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witting</LastName><ForeName>Nanna</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vissing</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querin</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soraru</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>Tiyonnoh M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minton</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozaffar</LastName><ForeName>Tahseen</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiland</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chelnick</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iyadurai</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kissel</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budron</LastName><ForeName>Maher S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kokkinis</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30337273</ArticleId><ArticleId IdType="mid">NIHMS1509988</ArticleId><ArticleId IdType="pmc">PMC6415539</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30320-X</ArticleId><ArticleId IdType="pii">S1474-4422(18)30320-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009; 132: 3242&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006; 129: 1446&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy&#x2019;s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87: 3893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009; 65: 140&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 875&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 140&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry 2017; 0: 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Burnett BG, Young JE, et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 2007; 16: 1593&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009; 63: 316&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Bott LC, Chen KL, Harmison GG, Katsuno M. Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol Med 2012; 18: 1261&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521783</ArticleId><ArticleId IdType="pubmed">22952056</ArticleId></ArticleIdList></Reference><Reference><Citation>Preisler N, Andersen G, Th&#xf8;gersen F, Crone C, Jeppesen TD, Vissing J. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 2009; 72: 317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">19171827</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab 1996; 81: 3492&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">8855791</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrader JA, Kats I, Kokkinis A, et al. A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 2015; 2: 739&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531056</ArticleId><ArticleId IdType="pubmed">26273686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71: 1770&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151128</ArticleId><ArticleId IdType="pubmed">12235108</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinologica 1989; 121: 753&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">2558477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3: 1009&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715022</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Di Somma C, Cascella T, et al. Relationship between serum IGF-1 levels, blood pressure, and glucose tolerance: an observational, exploratory study of 404 subjects. Eur J Endocrinol 2008; 159: 389&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">18603571</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014; 83: 2239&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277670</ArticleId><ArticleId IdType="pubmed">25381300</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris-Love MO, Fernandez-Rhodes L, Joe G, et al. Assessing function and endurance in adults with spinal and bulbar muscular atrophy: validity of the adult myopathy assessment tool. Rehabil Res Pract 2014; 2014: 873872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026974</ArticleId><ArticleId IdType="pubmed">24876969</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 1989; 83: 1717&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC303881</ArticleId><ArticleId IdType="pubmed">2651479</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biology 2001; 3: 1009&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K-MV, Gonzalez M, Poueymirou WT, et al. Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy. Mol Cell Biol 2004; 24: 9295&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522257</ArticleId><ArticleId IdType="pubmed">15485899</ArticleId></ArticleIdList></Reference><Reference><Citation>Joassard OR, Durieux A-C, Freyssenet DG. &#x3b2;2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol 2013; 45: 2309&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23845739</ArticleId></ArticleIdList></Reference><Reference><Citation>Milioto C, Malena A, Maino E, et al. Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. Sci Rep 2017; 7: 41046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5259768</ArticleId><ArticleId IdType="pubmed">28117338</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, D&#x2019;Ascenzo C, Peterle E, et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology 2013; 80: 2095&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23645595</ArticleId></ArticleIdList></Reference><Reference><Citation>Guber RD, Kokkinis AD, Schindler AB, et al. Patient-identified impact of symptoms in spinal and bulbar muscular atrophy. Muscle Nerve 2018; 57: 40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763365</ArticleId><ArticleId IdType="pubmed">28877556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-Y, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950456</ArticleId><ArticleId IdType="pubmed">17717599</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatuji H, Araki A, Hashizume A, et al. Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J Neurol 2017; 264: 839&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">28229243</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-1 in children with severe IGF-1 deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>